Atea Pharmaceuticals, Inc. (AVIR) Financials

AVIR Assets vs Liabilities

DateAssetsLiabilities
2023-12-31 595.0 million 39.8 million
2023-09-30 608.1 million 26.3 million
2023-06-30 626.0 million 23.7 million
2023-03-31 638.1 million 19.9 million

AVIR Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-12-31 -21.8 million 12.2 million
2023-09-30 -17.6 million 12.4 million
2023-06-30 -16.1 million 12.4 million
2023-03-31 -29.9 million 12.5 million

AVIR Net Income

No data available :(

AVIR Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-12-31 578.1 million - 2.4 million
2023-09-30 595.1 million - 2.6 million
2023-06-30 608.1 million - 2.8 million
2023-03-31 620.5 million - 2.9 million

AVIR Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-12-31 83.4 million
2023-09-30 83.4 million
2023-06-30 83.4 million
2023-03-31 83.3 million

AVIR Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-12-31 - 35.0 million 11.5 million 104000
2023-09-30 - 28.2 million 12.6 million -
2023-06-30 - 22.1 million 13.2 million -
2023-03-31 - 29.0 million 12.6 million -

AVIR Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-12-31 - 104000
2023-09-30 - 104000
2023-06-30 - 104000
2023-03-31 - 104000

AVIR

Price: $3.71

52 week price:
2.77
5.19

Earnings Per Share: -1.63 USD

P/E Ratio: -2.56

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Volume: 884000

Ebitda: -17.0 million

Market Capitalization: 316.9 million

Links: